Premium
Important technical remarks on distal pancreatectomy with en‐bloc celiac axis resection for locally advanced pancreatic body cancer (with video)
Author(s) -
Tanaka Eiichi,
Hirano Satoshi,
Tsuchikawa Takahiro,
Kato Kentaro,
Matsumoto Joe,
Shichinohe Toshiaki
Publication year - 2012
Publication title -
journal of hepato‐biliary‐pancreatic sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 1868-6974
DOI - 10.1007/s00534-011-0473-7
Subject(s) - medicine , celiac artery , left gastric artery , pancreatectomy , gastroduodenal artery , superior mesenteric artery , pancreatic cancer , common hepatic artery , surgery , dissection (medical) , artery , cancer , radiology , resection
Background We have already reported the feasibility, safety, and excellent long‐term results of distal pancreatectomy with en‐bloc celiac axis resection (DP‐CAR) for locally advanced pancreatic body cancer. An international standard for the surgical technique of DP‐CAR has yet to be established. Methods DP‐CAR was carefully performed in 42 patients in Hokkaido University Hospital from 1998 to July 2007. Arterial blood flow alteration and collateral flow development toward the liver and stomach was obtained following preoperative routine transcatheter arterial embolization of the common hepatic artery. The right‐sided approach to the superior mesenteric artery and celiac artery, and the preservation of the inferior pancreatoduodenal artery during the dissection of the plexus around the pancreatic head, are the key techniques in DP‐CAR. Results The operative morbidity and mortality were 43 and 4.8%, respectively. R0 resection could be done in 39 (93%) patients. Median operation time and intraoperative blood loss were 478 min and 1030 ml, respectively. Ischemic gastropathy was complicated in 5 (12%) patients, but liver abscess was found in only one patient and no liver failure was encountered. Conclusions We emphasize again the feasibility and safety of DP‐CAR; it should be a treatment of choice for locally advanced pancreatic body cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom